| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO | President & CEO +3 more
4 companies
Edward M. Kaye MD is Director at STOK, with reported holdings spanning 4 companies. Edward M. Kaye MD's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.4M at current prices.
Our model assigns Edward M. Kaye MD a below-average insider score of 45/100, based on 26 past trades. Over a 12-month horizon, 16.7% of those trades were profitable, with an average 12-month return of -42.0%.
Edward M. Kaye MD's largest disclosed position is in STOK as Director, worth about $3.4M. The STOK filings lean toward selling, a net 320,351 shares.
Edward M. Kaye MD has 100 Form 4 filings on record from February 2015 to October 2026, across 4 companies: Director at Cytokinetics (CYTK), 2020–2026; Director at Stoke Therapeutics (STOK), 2019–2026; Director at Avidity Biosciences (RNA), 2021–2025, and 1 more.
The 158 reported transactions were 47 open-market sales, 34 option or other derivative awards, 33 stock awards and 29 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $9K and 30 sales worth about $18.7M.
The only open-market purchase was 800 shares of SRPT at an average $11.81 on February 27, 2015, about $9K.
The largest open-market sale was 40,179 shares of SRPT at an average $60.00 on September 22, 2016, about $2.4M.
13 of the 20 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 7 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | STOK Stoke Therapeutics, Inc. | Director | Sale+OE | 12,567 | $32.03 | $402,528.08 | -9.2% | - | - | |
| Jun 1, 2026 | CYTK Cytokinetics, Incorporated | Director | Sell10b5-1 | 2,933 | $76.09 | $223,171.97 | -22.2% | -3.8% | - | |
| Dec 8, 2025 | STOK Stoke Therapeutics, Inc. | Director | Sell10b5-1 | 13,430 | $32.27 | $433,385.06 | -21.5% | +16.0% | - | |
| Dec 5, 2025 | STOK Stoke Therapeutics, Inc. | Director | Sale+OE10b5-1 | 15,001 | $31.13 | $466,958.91 | -19.3% | +12.2% | - | |
| Dec 3, 2025 | STOK Stoke Therapeutics, Inc. | Director | Sale+OE | 2,136 | $30.22 | $64,541.43 | -4.0% | +9.1% | - | |
| Dec 1, 2025 | CYTK Cytokinetics Inc | Director | Sale+OE10b5-1 | 28,064 | $66.72 | $1,872,430.08 | -73.8% | -6.9% | - | |
| Nov 11, 2025 | CYTK Cytokinetics Inc | Director | Sale+OE10b5-1 | 5,175 | $65.08 | $336,789.00 | -34.2% | -4.7% | - | |
| Oct 8, 2025 | STOK Stoke Therapeutics, Inc. | Director | Sale+OE10b5-1 | 25,000 | $30.00 | $750,000.00 | -33.7% | +15.5% | -21.5% | |
| Oct 6, 2025 | CYTK Cytokinetics Inc | Director | Sell10b5-1 | 6,757 | $60.00 | $405,420.00 | -40.9% | +1.0% | +1.2% | |
| Oct 3, 2025 | STOK Stoke Therapeutics, Inc. | Director | Sell10b5-1 | 42,461 | $25.09 | $1,065,206.37 | -46.4% | +20.9% | +0.2% |